242 related articles for article (PubMed ID: 11223882)
1. Ectopeptidases in pathophysiology.
Antczak C; De Meester I; Bauvois B
Bioessays; 2001 Mar; 23(3):251-60. PubMed ID: 11223882
[TBL] [Abstract][Full Text] [Related]
2. Ectopeptidases in tumour biology: a review.
Carl-McGrath S; Lendeckel U; Ebert M; Röcken C
Histol Histopathol; 2006 Dec; 21(12):1339-53. PubMed ID: 16977585
[TBL] [Abstract][Full Text] [Related]
3. Transmembrane proteases as disease markers and targets for therapy.
Antczak C; De Meester I; Bauvois B
J Biol Regul Homeost Agents; 2001; 15(2):130-9. PubMed ID: 11501970
[TBL] [Abstract][Full Text] [Related]
4. Accumulating insights into the role of phospholipase D2 in human diseases.
Ghim J; Chelakkot C; Bae YS; Suh PG; Ryu SH
Adv Biol Regul; 2016 May; 61():42-6. PubMed ID: 26695710
[TBL] [Abstract][Full Text] [Related]
5. PRDM proteins: important players in differentiation and disease.
Fog CK; Galli GG; Lund AH
Bioessays; 2012 Jan; 34(1):50-60. PubMed ID: 22028065
[TBL] [Abstract][Full Text] [Related]
6. Regulation of sphingosine kinase in hematological malignancies and other cancers.
Pitson SM; Powell JA; Bonder CS
Anticancer Agents Med Chem; 2011 Nov; 11(9):799-809. PubMed ID: 21707491
[TBL] [Abstract][Full Text] [Related]
7. Differential exoprotease activities confer tumor-specific serum peptidome patterns.
Villanueva J; Shaffer DR; Philip J; Chaparro CA; Erdjument-Bromage H; Olshen AB; Fleisher M; Lilja H; Brogi E; Boyd J; Sanchez-Carbayo M; Holland EC; Cordon-Cardo C; Scher HI; Tempst P
J Clin Invest; 2006 Jan; 116(1):271-84. PubMed ID: 16395409
[TBL] [Abstract][Full Text] [Related]
8. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
Thompson MA; Ohnuma K; Abe M; Morimoto C; Dang NH
Mini Rev Med Chem; 2007 Mar; 7(3):253-73. PubMed ID: 17346218
[TBL] [Abstract][Full Text] [Related]
9. New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.
Pimentel A; Velez M; Barahona LJ; Swords R; Lekakis L
Future Oncol; 2013 May; 9(5):681-97. PubMed ID: 23647297
[TBL] [Abstract][Full Text] [Related]
10. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
11. Kidney ectopeptidases. Structure, functions and clinical significance.
Vlahović P; Stefanović V
Pathol Biol (Paris); 1998 Dec; 46(10):779-86. PubMed ID: 9922994
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiological role of A-to-I RNA editing enzyme ADAR1 in human diseases].
Iizasa H
Seikagaku; 2016 Oct; 88(5):593-9. PubMed ID: 29624323
[No Abstract] [Full Text] [Related]
13. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):657-61. PubMed ID: 17605888
[TBL] [Abstract][Full Text] [Related]
14. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
Benati D; Baldari CT
Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress on miR-125 Family in Malignant Hematologic Diseases-Review].
Liu AF; Wang JX; Li FL; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1842-1846. PubMed ID: 29262928
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
Rodrigues MS; Reddy MM; Sattler M
Antioxid Redox Signal; 2008 Oct; 10(10):1813-48. PubMed ID: 18593226
[TBL] [Abstract][Full Text] [Related]
17. Cell membrane-bound proteases: not "only" proteolysis.
Sedo A; Mandys V; Krepela E
Physiol Res; 1996; 45(3):169-76. PubMed ID: 9200207
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases as therapeutic targets in hematologic malignancies.
Melnick A; Licht JD
Curr Opin Hematol; 2002 Jul; 9(4):322-32. PubMed ID: 12042707
[TBL] [Abstract][Full Text] [Related]
19. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
20. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies.
Sun C; Duan P; Luan C
Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
